Cited by 751Pharmacogenetics and Drug MetabolismCoffee research and impactsGenetic Associations and Epidemiology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Open access

Sachse, Christoph, Brockmöller, Jürgen, Bauer, Steffen, Roots, Ivar·1999·British Journal of Clinical Pharmacology

DOI 10.1046/j.1365-2125.1999.00898.xPMC PMC2014233

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: The cytochrome P450 enzyme CYP1A2 metabolises several drugs and carcinogens. We wanted to determine how much of the variability of CYP1A2 activity is explained by a newly discovered gene polymorphism in intron 1. METHODS: A single nucleotide polymorphism in intron 1 of the CYP1A2 gene at position 734 downstream of the first transcribed nucleotide was identified by DNA sequence analysis. The functional significance of this C/A polymorphism was assessed in 185 healthy Caucasian non-smokers and in 51 smokers by genotyping and phenotyping using caffeine (100 mg oral dose). RESULTS: Out of the total sample, 46% were homozygous for the variant A, 44% were heterozygous, and 10% were homozygous for the variant C. The ratio of 1,7-dimethylxanthine (17X) plus 1,7-dimethyluric acid divided by caffeine in 0-5 h urine samples from 185 non-smokers did not differ significantly between the three CYP1A2 genotypes. In the 51 smokers, analysis of variance revealed significant differences in the 5 h plasma 17X/caffeine ratios between the genotypes (P=0.008, F-test). The mean ratio was 1.37 in carriers of the A/A genotype, 0.88 in heterozygotes and 0.82 in carriers of C/C. The mean difference between the A/A and C/A groups was 0.48 (95% confidence interval 0. 15-0.81; P=0.01). CONCLUSIONS: The A/A genotype, which may represent a CYP1A2 high inducibility genotype, may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. Further studies are needed to define the role of this polymorphism on the pharmacokinetics of drugs metabolised by CYP1A2 and in the activation of carcinogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1999.00898.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
Bertz, R., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 754
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M. F., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman‐Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity
Eaton, D. L., Gallagher, E. P., Bammler, T. K., & Kunze, K. L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199510000-00001 · Cited by 271
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
KALOW, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 264
A simple test for acetylator phenotype using caffeine.
Grant, D. M., Tang, B., & KALOW, W. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02372.x · Cited by 212
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
Fuhr, U., & Rost, K. L. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00001 · Cited by 182
HumanCYP1A2: Sequence, Gene Structure, Comparison with the Mouse and Rat Orthologous Gene, and Differences in Liver1A2mRNA Expression
Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., & Kimura, S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-9-1399 · Cited by 147
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141
Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132

Show all 16 references

Research works printed but not linked: 2

MacLeod SL, 1998, . The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene., Proceedings of the American Association for Cancer Research, 39, 396
SambrookJ FritschEF ManiatisTMolecular cloning: a laboratory manual 2nd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor 1989

Sorted by citations

Items 101–200 of 749

Interindividual Variability in Biomarkers of Cardiometabolic Health after Consumption of Major Plant-Food Bioactive Compounds and the Determinants Involved
Milenković, D., Morand, C., Cassidy, A., Konić‐Ristić, A., Tomás-Barberán, F. A., Ordovás, J. M., Kroon, P. A., Caterina, R. D., & Rodriguez‐Mateos, A. (2017) · Advances in Nutrition · doi:10.3945/an.116.013623 · Cited by 113
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism
Djordjević, N., Ghotbi, R., Јаnkovic, S., & Aklillu, E. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0823-4 · Cited by 108
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome
Laika, B., Leucht, S., Heres, S., Schneider, H., & Steimer, W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.32 · Cited by 108
Coffee, caffeine, and coronary heart disease
Cornelis, M. C., & El‐Sohemy, A. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3280127b04 · Cited by 110
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer.
Kadlubar, F. F., Berkowitz, G. S., Delongchamp, R. R., Wang, C., Green, B. L., Tang, G. Y., Lamba, J. K., Schuetz, E. G., & Wolff, M. S. (2003) · PubMed · Cited by 107
Predicting drug response and toxicity based on gene polymorphisms
Robert, J., Morvan, V. L., Smith, D. M., Pourquier, P., & Bonnet, J. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.01.005 · Cited by 106
Caffeine and 3‐km cycling performance: Effects of mouth rinsing, genotype, and time of day
Pataky, M. W., Womack, C. J., Saunders, M., Goffe, J. L., D’Lugos, A. C., El‐Sohemy, A., & Luden, N. D. (2015) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.12501 · Cited by 105
The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Hormonal regulation of CYP1A expression
Monostory, K., Pascussi, J., Kob́ori, L., & Dvořák, Z. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530903112284 · Cited by 102
Impacts of Caffeine during Pregnancy
Qian, J., Chen, Q., Ward, S. M., Duan, E., & Zhang, Y. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.11.004 · Cited by 101
Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine
Özdemir, V., KALOW, W., Okey, A. B., Lam, M. S. M., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., & Roy, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00011 · Cited by 99
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
Uncertainty factors for chemical risk assessment
Dorne, J. L. C. M., Walton, K., & RENWICK, A. G. (2001) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(01)00005-9 · Cited by 98
Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption
Josse, A. R., Costa, L. A. D., Campos, H., & El‐Sohemy, A. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038794 · Cited by 101
Polymorphisms of cytochrome P4501A2 and N -acetyltransferase genes, smoking, and risk of pancreatic cancer
Li, D., Jiao, L., Li, Y., Doll, M. A., Hein, D. W., Bondy, M. L., Evans, D. B., Wolff, R. A., Lenzi, R., Pisters, P. W. T., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi171 · Cited by 97
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine
Masellis, M., Basile, V. S., Özdemir, V., Meltzer, H. Y., Macciardi, F. M., & Kennedy, J. L. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00298-x · Cited by 95
Loss of response to melatonin treatment is associated with slow melatonin metabolism
Braam, W., Van Geijlswijk, I., Keijzer, H., Smits, M. G., Didden, R., & Curfs, L. M. G. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01283.x · Cited by 94
Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped Patients
Bondolfi, G., Morel, F., Crettol, S., Rachid, F., Baumann, P., & Eap, C. B. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000164609.14808.93 · Cited by 94
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients
Grabar, P. B., Rozman, B., Tomšič, M., Šuput, D., Logar, D., & Dolžan, V. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0498-2 · Cited by 89
Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2
Han, X., Ouyang, D., Lu, P., Jiang, C.-H., Shu, Y., Chen, X., Tan, Z.-R., & Zhou, H. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00006 · Cited by 89
METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?
Tang, C., Lin, J. H., & Lu, A. Y. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003236 · Cited by 89
DNA Sequence Variation in a 3.7-kb Noncoding Sequence 5′ of the CYP1A2 Gene: Implications for Human Population History and Natural Selection
Wooding, S., Watkins, W. S., Bamshad, M. J., Dunn, D. M., Weiss, R. B., & Jorde, L. B. (2002) · The American Journal of Human Genetics · doi:10.1086/342260 · Cited by 87
Caffeine: Friend or Foe?
Doepker, C., Lieberman, H. R., Smith, A. P., Peck, J. D., El-Sohemy, A., & Welsh, B. T. (2016) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-041715-033243 · Cited by 87
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility
Hirata, H., Hinoda, Y., Okayama, N., Suehiro, Y., Kawamoto, K., Kikuno, N., Rabban, J. T., Chen, L. M., & Dahiya, R. (2008) · Cancer · doi:10.1002/cncr.23392 · Cited by 87
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism
Tiwari, A. K., Deshpande, S. N., Lerer, B., Nimgaonkar, V. L., & Thelma, B. K. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500415 · Cited by 87
The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers
Kotsopoulos, J., Ghadirian, P., El‐Sohemy, A., Lynch, H. T., Snyder, C., Daly, M. B., Domchek, S. M., Randall, S., Karlan, B. Y., Zhang, P., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1074 · Cited by 87
Genetic Variation in Melatonin Pathway Enzymes in Children with Autism Spectrum Disorder and Comorbid Sleep Onset Delay
Veatch, O. J., Pendergast, J. S., Allen, M. J., Leu, R. M., Johnson, C. H., Elsea, S. H., & Malow, B. A. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2197-4 · Cited by 89
Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes
Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055798 · Cited by 86
Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia
Özdemir, V., KALOW, W., Posner, P., Collins, E. J., Kennedy, J. L., Tang, B.-K., Albers, L. J., Reist, C., Roy, R., Walkes, W., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00007 · Cited by 85
Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction
Cornelis, M. C., El‐Sohemy, A., & Campos, H. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.022012 · Cited by 84
Caffeine and Exercise Performance: Possible Directions for Definitive Findings
Martins, G. L., Guilherme, J. P. L. F., Ferreira, L. H. B., de Souza, T. P., & Lancha, A. H. (2020) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2020.574854 · Cited by 95
The Role of Genetics in Moderating the Inter-Individual Differences in the Ergogenicity of Caffeine
Southward, K., Rutherfurd-Markwick, K., Badenhorst, C., & Ali, A. (2018) · Nutrients · doi:10.3390/nu10101352 · Cited by 81
Low maternal melatonin level increases autism spectrum disorder risk in children
Braam, W., Ehrhart, F., Evelo, C. T., Maas, A. P. H. M., Smits, M. G., & Curfs, L. (2018) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2018.02.017 · Cited by 100
CYP Gene Polymorphisms and Early Menarche
Lai, J., Vesprini, D., Chu, W., Jernström, H., & Narod, S. A. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3260 · Cited by 80
Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk
Rebbeck, T. R., Troxel, A. B., Wang, Y., Walker, A. H., Panossian, S., Gallagher, S., Shatalova, E. G., Blanchard, R. L., Bunin, G. R., DeMichele, A. M., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj360 · Cited by 80
Frequencies of 23 Functionally Significant Variant Alleles Related with Metabolism of Antineoplastic Drugs in the Chilean Population: Comparison with Caucasian and Asian Populations
Roco, Á., Quiñones, L. A., Agúndez, J. A. G., García‐Martín, E., Squicciarini, V., Miranda, C., Garay, J. R., Farfán, N., Saavedra, I. N., Cáceres, D., et al. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00229 · Cited by 80
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
Härtter, S., Nordmark, A., Rose, D., Bertilsson, L., Tybring, G., & Laine, K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01933.x · Cited by 79
Single Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population
Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., et al. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.24 · Cited by 79
A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers
de Leon, J., Diaz, F. J., Rogers, T., Browne, D., Dinsmore, L., Ghosheh, O. H., Dwoskin, L. P., & Crooks, P. A. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00348-2 · Cited by 77
Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer
Doherty, J. A., Weiss, N. S., Freeman, R. J., Dightman, D. A., Thornton, P. J., Houck, J. R., Voigt, L. F., Rossing, M. A., Schwartz, S. M., & Chen, C. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0479 · Cited by 78
Caffeine consumption during pregnancy and risk of preterm birth: a meta-analysis
Maslova, E., Bhattacharya, S., Lin, S., & Michels, K. B. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29789 · Cited by 76
Pharmacogenetics of antipsychotic-induced weight gain
Müller, D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.05.001 · Cited by 78
Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption
Küry, S., Buecher, B., Robiou-du-Pont, S., Scoul, C., Sebille, V., Colman, H., Houérou, C. L., Neel, T. L., Bourdon, J., Faroux, R., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0236 · Cited by 75
CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder?
Braam, W., Keijzer, H., Struijker-Boudier, H. A. J., Didden, R., Smits, M. G., & Curfs, L. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01595.x · Cited by 75
Polymorphisms in xenobiotic conjugation and disease predisposition
Brockmöller, J., Cascorbi, I., Kerb, R., Sachse, C., & Roots, I. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00304-x · Cited by 75
Influence of Genetic Polymorphisms, Smoking, Gender And Age on Cyp1A2 Activity in a Turkish Population
Gunes, A., Özbey, G., Vural, E. H., Uluoğlu, C., Scordo, M. G., Zengil, H., & Dahl, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.22 · Cited by 74
Molecular Genetics of Cancer Susceptibility
Brockmöller, J., Cascorbi, I., Henning, S. W., Meisel, C., & Roots, I. (2000) · Pharmacology · doi:10.1159/000028403 · Cited by 74
Association Study of 27 Annotated Genes for Clozapine Pharmacogenetics
Lee, S., Ryu, S., Kim, S.-R., Kim, M.-J., Kim, S., Kim, J., Lee, S., & Hong, K. S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ac35c · Cited by 73
The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics
Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R., Shibata, N., & Arai, H. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31816336fd · Cited by 73
Enhanced Clopidogrel Responsiveness in Smokers
Park, K. W., Park, J. J., Jeon, K., Kang, S., Oh, I., Yang, H., Cho, H., Lee, H., Kang, H., Koo, B., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.217182 · Cited by 73
Minimal Effect of Acute Caffeine Ingestion on Intense Resistance Training Performance
Astorino, T. A., Martin, B. J., Schachtsiek, L., Wong, K., & Ng, K. (2011) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0b013e3181ddf6db · Cited by 69
CYP enzyme polymorphisms and susceptibility to HCV‐related chronic liver disease and liver cancer
Silvestri, L., Sonzogni, L., Silvestri, A. D., Gritti, C., Foti, L., Zavaglia, C., Leveri, M., Cividini, A., Mondelli, M. U., Civardi, E., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10937 · Cited by 72
Cancer of the Lung
Spitz, M. R., Wu, X., Wilkinson, A. V., & Wei, Q. (2006) · doi:10.1093/acprof:oso/9780195149616.003.0033 · Cited by 72
Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension
Guessous, I., Dobrinas, M., Kutalik, Z., Pruijm, M., Ehret, G., Maillard, M., Bergmann, S., Beckmann, J. S., Cusi, D., Rizzi, F., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds137 · Cited by 70
Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
Klomp, F., Wenzel, C., Droździk, M., & Oswald, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121201 · Cited by 70
Association of Caffeine Intake and CYP1A2 Genotype With Ovarian Cancer
Goodman, M. T., Tung, K., McDuffie, K., Wilkens, L. R., & Donlon, T. A. (2003) · Nutrition and Cancer · doi:10.1207/s15327914nc4601_03 · Cited by 70
Effect of two doses of caffeine on muscular function during isokinetic exercise.
Astorino, T., Terzi, M. N., Roberson, D. W., & Burnett, T. R. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e3a11d · Cited by 72
Coffee, CYP1A2 genotype and risk of myocardial infarction
El‐Sohemy, A., Cornelis, M. C., Kabagambe, E. K., & Campos, H. (2007) · Genes & Nutrition · doi:10.1007/s12263-007-0043-4 · Cited by 70
Impact of Genetic Variability on Physiological Responses to Caffeine in Humans: A Systematic Review
Fulton, J. L., Dinas, P. C., Carrillo, A. E., Edsall, J. R., Ryan, E. J., & Ryan, E. J. (2018) · Nutrients · doi:10.3390/nu10101373 · Cited by 76
Genetic determinants of blood pressure responses to caffeine drinking
Renda, G., Zimarino, M., Antonucci, I., Tatasciore, A., Ruggieri, B., Bucciarelli, T., Prontera, T., Stuppia, L., & Caterina, R. D. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.018267 · Cited by 69
Cytochrome P450 pharmacogenetics in African populations
Alessandrini, M., Asfaha, S. M., Dodgen, T. M., Warnich, L., & Pepper, M. S. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.783062 · Cited by 67
Blood Pressure in Relation to Coffee and Caffeine Consumption
Guessous, I., Eap, C. B., & Bochud, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0468-2 · Cited by 69
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients
Ghotbi, R., Mannheimer, B., Aklillu, E., Suda, A., Bertilsson, L., Eliasson, E., & Ösby, U. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0783-8 · Cited by 68
Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study
Hallström, H., Melhus, H., Glynn, A. W., Lind, L., Syvänen, A., & Michaëlsson, K. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-12 · Cited by 66
Genes and Eating Preferences, Their Roles in Personalized Nutrition
Vesnina, A. D., Prosekov, A. Y., Kozlova, O., & Atuchin∥⊥, V. V. (2020) · Genes · doi:10.3390/genes11040357 · Cited by 66
Population-based case–control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk
Long, J., Egan, K. M., Dunning, L., Shu, X., Cai, Q., Cai, H., Dai, Q., Holtzman, J. L., Gao, Y.-T., & Zheng, W. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000189803.34339.ed · Cited by 66
PhRMA White Paper on ADME Pharmacogenomics
Williams, J. A., Andersson, T., Andersson, T. B., Blanchard, R. L., Behm, M. O., Cohen, N., Edeki, T. I., Franc, M. A., Hillgren, K. M., Johnson, K. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008319329 · Cited by 65
Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression
Williams, J. A. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.209 · Cited by 65
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism
Tiwari, A. K., Deshpande, S. N., Rao, A. R., Triptish Bhatia, A., Mukit, S. R., Shriharsh, V., Lerer, B., Nimagaonkar, V. L., & Thelma, B. K. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500282 · Cited by 65
Identification of a novel splice‐site mutation in the CYP1A2 gene
Allorge, D., Chevalier, D., Lo‐Guidice, J., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B., & Broly, F. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01858.x · Cited by 65
Influence of Environmental and Genetic Factors on CYP1A2 Activity in Individuals of South Asian and European Ancestry
Perera, V., Gross, A. S., & McLachlan, A. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.139 · Cited by 64
Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers
Pavanello, S., Pulliero, A., Lupi, S., Gregorio, P., & Clonfero, E. (2005) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2005.08.008 · Cited by 64
Caffeine intake, CYP1A2 polymorphism and the risk of recurrent pregnancy loss
Sata, F., Yamada, H., Suzuki, K., Saijo, Y., Kato, E. H., Morikawa, M., Minakami, H., & Kishi, R. (2005) · Molecular Human Reproduction · doi:10.1093/molehr/gah175 · Cited by 64
Sources of Interindividual Variability
Thummel, K. E., & Lin, Y. S. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-758-7_17 · Cited by 65
Genetic variability in susceptibility and response to toxicants
Ingelman‐Sundberg, M. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00278-8 · Cited by 64
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants
Baumann, P., Ulrich, S., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., Rao, M. L., Riederer, P. F., Zernig, G., et al. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/pbaumann · Cited by 64
The G−113A polymorphism in affects the caffeine metabolic ratio in a Chinese population
Chen, X., WANG, L., ZHI, L., Zhou, G.-D., WANG, H., ZHANG, X., Hao, B., Zhu, Y., Cheng, Z., & HE, F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.012 · Cited by 63
Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients
Palatini, P., Benetti, E., Mos, L., Garavelli, G., Mazzer, A., Cozzio, S., Fania, C., & Casiglia, E. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-9990-z · Cited by 63
Pharmacogenetics of asthma
Fenech, A. G., & Hall, I. P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01509.x · Cited by 63
The effect of caffeine on cognitive performance is influenced by CYP1A2 but not ADORA2A genotype, yet neither genotype affects exercise performance in healthy adults
Carswell, A. T., Howland, K., Martinez-Gonzalez, B., Baron, P., & Davison, G. (2020) · European Journal of Applied Physiology · doi:10.1007/s00421-020-04384-8 · Cited by 61
Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers
Tan, E., Chua, E., Fook-Chong, S. M. C., Teo, Y., Yih, Y., Tan, L. C. S., & Zhao, Y. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f09265 · Cited by 61
Caffeinated beverage intake and reproductive hormones among premenopausal women in the BioCycle Study
Schliep, K. C., Schisterman, E. F., Mumford, S. L., Pollack, A. Z., Zhang, C., Ye, A., Stanford, J. B., Hammoud, A. O., Porucznik, C. A., & Wactawski‐Wende, J. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.021287 · Cited by 62
The effect of CYP1A2 genotype on the ergogenic properties of caffeine during resistance exercise: a randomized, double-blind, placebo-controlled, crossover study
Rahimi, R. (2019) · Irish Journal of Medical Science · doi:10.1007/s11845-018-1780-7 · Cited by 55
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia
Schulze, T. G., Schumacher, J. H., Müller, D. J., Krauß, H., Alfter, D., Maroldt, A., Ahle, G., Maroldt, A., y Fernández, A. N., Weber, T., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1472 · Cited by 62
Novel insights on caffeine supplementation, CYP1A2 genotype, physiological responses and exercise performance
Barreto, G., Grecco, B. H., Merola, P., Reis, C. E. G., Gualano, B., & Saunders, B. (2021) · European Journal of Applied Physiology · doi:10.1007/s00421-020-04571-7 · Cited by 66
Pharmacogenetics of Drug Metabolism
Bertilsson, L., & Panagiotidis, G. (2005) · Drugs and the pharmaceutical sciences · doi:10.1201/9780849359507.ch3 · Cited by 61
Association between coffee or caffeine consumption and fecundity and fertility: a systematic review and dose–response meta-analysis
Lyngsø, J., Ramlau‐Hansen, C. H., Bay, B., Ingerslev, H. J., Hulmán, Á., & Kesmodel, U. S. (2017) · Clinical Epidemiology · doi:10.2147/clep.s146496 · Cited by 60
The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women
Nordmark, A., Lundgren, S., Ask, B., Granath, F. N., & Rane, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01673.x · Cited by 60
CYP1A2 Genotype and Acute Effects of Caffeine on Resistance Exercise, Jumping, and Sprinting Performance
Grgic, J., Pickering, C., Bishop, D. J., Schoenfeld, B. J., Mikulic, P., & Pedisic, Z. (2020) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00349-6 · Cited by 60
Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics
Gervasini, G., Carrillo, J. A., & Benítez, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00001 · Cited by 59
Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer
Yuan, J., Chan, K. K. L., Coetzee, G. A., Castelao, J. E., Watson, M. A., Bell, D. A., Wang, R., & Yu, M. C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn136 · Cited by 59
The Biochemistry of Drug Metabolism – An Introduction
Krämer, S. D., & Testa, B. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890214 · Cited by 59
Precision Nutrition Unveiled: Gene–Nutrient Interactions, Microbiota Dynamics, and Lifestyle Factors in Obesity Management
Mansour, S., Alkhaaldi, S. M. I., Sammanasunathan, A. F., Ibrahim, S. M., Farhat, J., & Al‐Omari, B. (2024) · Nutrients · doi:10.3390/nu16050581 · Cited by 69
Genetics of Tardive Dyskinesia
Lee, H., & Kang, S. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00010-9 · Cited by 58
Consumption of dietary caffeine and coffee in physically active populations: physiological interactions
Tunnicliffe, J. M., Erdman, K. A., Reimer, R. A., Lun, V. M. Y., & Shearer, J. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-124 · Cited by 61
Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung
Wei, C., Caccavale, R. J., Weyand, E. H., Chen, S., & Iba, M. M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00809-6 · Cited by 58
Clinical implications of pharmacogenomics for tardive dyskinesia
Müller, D., Shinkai, T., Luca, V. D., & Kennedy, J. L. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500233 · Cited by 58
Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking.
Yoshida, K., Osawa, K., Kasahara, M., Miyaishi, A., Nakanishi, K., Hayamizu, S., Osawa, Y., Tsutou, A., Tabuchi, Y., Shimada, E., et al. (2007) · PubMed · Cited by 57

Authors: Sachse, C., Brockmöller, J., Bauer, S., & Roots, I.
Affiliations: Humboldt-Universität zu Berlin (DE)
ORCID: Sachse, Christoph
Brockmöller, Jürgen
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1999-04
Volume: 47
Issue: 4
Pages: 445-449
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1046/j.1365-2125.1999.00898.x
PMC: PMC2014233
OpenAlex: W1734451748
Cited by: 751
References: 16
Citations by year: 2026: 12 · 2025: 21 · 2024: 27 · 2023: 27 · 2022: 18 · 2021: 21 · 2020: 39 · 2019: 17 · 2018: 30 · 2017: 20 · 2016: 31 · 2015: 27 · 2014: 27 · 2013: 26 · 2012: 42
FWCI: 19.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 998 d)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords: CYP1A2, cytochrome P450, intron 1 polymorphism, caffeine, 1,7-dimethylxanthine, enzyme inducibility, smokers, genetic variation in drug metabolism, pharmacogenetics, carcinogen activation
MeSH terms: Caffeine, Humans, Introns, Polymorphism, Genetic, Smoking, Cytochrome P-450 CYP1A2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks